company background image
PHAR

Egyptian International Pharmaceutical IndustriesCASE:PHAR Stock Report

Market Cap

ج.م4.3b

7D

0%

1Y

-8.5%

Updated

19 Oct, 2021

Data

Company Financials +
PHAR fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance1/6
Financial Health3/6
Dividends0/6

PHAR Overview

Egyptian International Pharmaceutical Industries Company produces and sells pharmaceuticals primarily in Egypt.

Price History & Performance

Summary of all time highs, changes and price drops for Egyptian International Pharmaceutical Industries
Historical stock prices
Current Share Priceج.م43.00
52 Week Highج.م39.00
52 Week Lowج.م50.98
Beta0.065
1 Month Change-7.13%
3 Month Change-4.49%
1 Year Change-8.51%
3 Year Change-51.14%
5 Year Change-20.96%
Change since IPO668.99%

Recent News & Updates

Shareholder Returns

PHAREG PharmaceuticalsEG Market
7D0%-1.3%2.5%
1Y-8.5%0.7%10.9%

Return vs Industry: PHAR underperformed the EG Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: PHAR underperformed the EG Market which returned 10.9% over the past year.

Price Volatility

Is PHAR's price volatile compared to industry and market?
PHAR volatility
PHAR Beta0.065
Industry Beta0.86
Market Beta1

Stable Share Price: PHAR is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PHAR's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980n/aAhmed Kelanihttps://www.eipico.com.eg

Egyptian International Pharmaceutical Industries Company produces and sells pharmaceuticals primarily in Egypt. It produces various dosage forms, such as the spansule capsules, soft gelatin capsules, lyophilized products, gels, sprayers, and effervescent tablets. The company’s products include anaesthetics, antibiotics, antifungals, antihistaminic products, antiparasitic products, antiviral products, blood-forming drugs, cardiovascular drugs, dental products, dermatology products, gastrointestinal drugs, genitourinary system drugs, hospital products, musculoskeletal drugs, nervous system drugs, ophthalmic products, oral antidiabetic products, psychiatry drugs, pulmonics, systemic corticosteroids, systemic hormones, vitamins, electrolytes and combinations, and other products, as well as analgesics, antipyretics, and anticatarrhal drugs.

Egyptian International Pharmaceutical Industries Fundamentals Summary

How do Egyptian International Pharmaceutical Industries's earnings and revenue compare to its market cap?
PHAR fundamental statistics
Market Capج.م4.26b
Earnings (TTM)ج.م495.28m
Revenue (TTM)ج.م3.04b

8.6x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PHAR income statement (TTM)
Revenueج.م3.04b
Cost of Revenueج.م1.70b
Gross Profitج.م1.34b
Expensesج.م844.81m
Earningsج.م495.28m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)4.99
Gross Margin44.11%
Net Profit Margin16.30%
Debt/Equity Ratio65.2%

How did PHAR perform over the long term?

See historical performance and comparison

Valuation

Is Egyptian International Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?

27.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PHAR (EGP43) is trading below our estimate of fair value (EGP59.1)

Significantly Below Fair Value: PHAR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PHAR is poor value based on its PE Ratio (8.6x) compared to the EG Pharmaceuticals industry average (5.7x).

PE vs Market: PHAR is good value based on its PE Ratio (8.6x) compared to the EG market (11.9x).


Price to Earnings Growth Ratio

PEG Ratio: PHAR is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: PHAR is overvalued based on its PB Ratio (1.5x) compared to the EG Pharmaceuticals industry average (1.3x).


Future Growth

How is Egyptian International Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

13.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHAR's forecast earnings growth (13.9% per year) is above the savings rate (9.1%).

Earnings vs Market: PHAR's earnings (13.9% per year) are forecast to grow slower than the EG market (14.3% per year).

High Growth Earnings: PHAR's earnings are forecast to grow, but not significantly.

Revenue vs Market: PHAR's revenue (13.7% per year) is forecast to grow faster than the EG market (10% per year).

High Growth Revenue: PHAR's revenue (13.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PHAR's Return on Equity is forecast to be high in 3 years time (26.1%)


Past Performance

How has Egyptian International Pharmaceutical Industries performed over the past 5 years?

-0.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PHAR has high quality earnings.

Growing Profit Margin: PHAR's current net profit margins (16.3%) are lower than last year (17.2%).


Past Earnings Growth Analysis

Earnings Trend: PHAR's earnings have declined by 0.3% per year over the past 5 years.

Accelerating Growth: PHAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PHAR had negative earnings growth (-7.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).


Return on Equity

High ROE: PHAR's Return on Equity (17.7%) is considered low.


Financial Health

How is Egyptian International Pharmaceutical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: PHAR's short term assets (EGP3.6B) exceed its short term liabilities (EGP2.1B).

Long Term Liabilities: PHAR's short term assets (EGP3.6B) exceed its long term liabilities (EGP56.0M).


Debt to Equity History and Analysis

Debt Level: PHAR's debt to equity ratio (65.2%) is considered high.

Reducing Debt: PHAR's debt to equity ratio has increased from 0.2% to 65.2% over the past 5 years.

Debt Coverage: PHAR's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: PHAR's interest payments on its debt are well covered by EBIT (7.9x coverage).


Balance Sheet


Dividend

What is Egyptian International Pharmaceutical Industries's current dividend yield, its reliability and sustainability?

11.03%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PHAR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PHAR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PHAR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHAR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: PHAR is not paying a notable dividend for the EG market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PHAR's dividend in 3 years as they are not forecast to pay a notable one for the EG market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Ahmed Kelani

no data

Tenure

Dr. Ahmed Said Kelani serves as the Chairman of the Board and Managing Director at Egyptian International Pharmaceutical Industries Company.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Egyptian International Pharmaceutical Industries Company's employee growth, exchange listings and data sources


Key Information

  • Name: Egyptian International Pharmaceutical Industries Company
  • Ticker: PHAR
  • Exchange: CASE
  • Founded: 1980
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م4.264b
  • Shares outstanding: 99.17m
  • Website: https://www.eipico.com.eg

Location

  • Egyptian International Pharmaceutical Industries Company
  • 1st Industrial Zone B1
  • 10th of Ramadan City
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 14:32
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.